The analysis of CONMED Corporation reveals a concerning profitability profile despite margins that remain near historical averages. Gross margin has slipped to 52.8%, placing it at the 0th percentile of its ten‑year range—a clear outlier that signals structural pressure on core pricing or cost structure. While operating and net margins are still above their respective ten‑year averages (10.3% vs 8.4% and 3.4% vs 3.6%), both have posted a year‑over‑year decline, indicating that the erosion in gross profitability is beginning to flow through to the bottom line. The single critical alert underscores that the company’s margin health warrants close monitoring over the next 6‑12 months.

Leverage analysis for CONMED Corporation reveals a mixed picture of improving capital structure alongside lingering solvency concerns. The debt-to-equity ratio has moved from 0.94x to 0.81x year‑over‑year, positioning the company at the 36th percentile of its ten‑year historical range and indicating a modest reduction in balance‑sheet risk. However, net debt relative to EBITDA remains elevated at 4.1x, only marginally above the commonly watched 4.0x threshold and far higher than the ten‑year average of 15.8x, signaling that earnings are still heavily leveraged despite recent improvements. The primary alert stems from the Net Debt/EBITDA metric breaching the 4.0x safety line, which could constrain financial flexibility if operating performance deteriorates. While interest coverage data were not provided, any decline in that ratio would exacerbate the risk profile given the already high net debt burden. Overall, CONMED’s leverage trajectory is trending downward on a equity basis but remains near a critical leverage boundary on an earnings basis.

Conmed Corporation generates modest but improving operating cash flow, currently $0.2 billion versus a 10‑year average of $0.1 billion and a year‑over‑year increase of $3.7 million. However, free cash flow has slipped slightly to $0.2 billion, down $3.0 million YoY, indicating that capital expenditures are consuming a larger share of cash generated from operations. The company’s short‑term liquidity remains comfortable, with a current ratio of 2.14x and a quick ratio of 1.01x, both above the conventional safety thresholds of 1.0x, though they sit below their respective 10‑year averages, suggesting a gradual weakening of buffer levels.

CONMED Corporation exhibits exceptionally strong earnings quality as reflected by its operating cash flow to net income ratio of 3.63x, far above the ten‑year average of 2.32x and indicating that reported profit is more than fully supported by cash generation. However, the negative accrual ratio of -5.3% suggests modest earnings manipulation through timing of expense recognition, a slight deterioration from its historical norm of -2.8%. The company’s stock‑based compensation (SBC) now consumes 2.1% of revenue, exceeding the ten‑year average of 1.5% and showing a deteriorating trend that could pressure margins if not managed. Capital intensity remains low, with CapEx representing only 12% of operating cash flow versus a historical average of 24%, implying ample free cash to fund growth or return capital to shareholders.